Akorn, Inc. (AKRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.23-0.51 (-1.91%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close26.74
Bid0.00 x
Ask0.00 x
Day's Range26.20 - 27.00
52wk Range17.57 - 39.46
1y Target EstN/A
Market Cap3.31B
P/E Ratio (ttm)17.68
Avg Vol (3m)1,183,360
Dividend & Yield0.00 (0.00%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com14 hours ago

    Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says

    In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.

  • Investopedia4 days ago

    Akorn Plant Cited For 6 FDA Violations (AKRX)

    Akorn Inc. was slapped with a warning letter after the FDA found 6 quality-control violations at its Decatur, Illinois, drug manufacturing plant.

  • GlobeNewswire12 days ago

    Akorn Announces Third Quarter 2016 Earnings Release and Conference Call Information

    LAKE FOREST, Ill., Oct. 13, 2016-- Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, November 3, 2016 outlining the third ...